MiMedx Group Inc (MDXG)

9.49
NASDAQ : Health Care
Prev Close 9.49
Day Low/High 0.00 / 0.00
52 Wk Low/High 6.64 / 10.02
Avg Volume 810.80K
Exchange NASDAQ
Shares Outstanding 109.51M
Market Cap 995.49M
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MiMedx Announces USP-NF Monograph For DHACM Allografts Has Published

MiMedx Announces USP-NF Monograph For DHACM Allografts Has Published

MIMEDX'S PURION PROCESSED dHACM ALLOGRAFTS REPRESENT YEARS OF SCIENTIFIC RIGOR THAT CONFORM TO THE NEW USP-NF MONOGRAPH

Notable Two Hundred Day Moving Average Cross - MDXG

Notable Two Hundred Day Moving Average Cross - MDXG

In trading on Thursday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.03, changing hands as low as $7.87 per share. MiMedx Group Inc shares are currently trading down about 5.9% on the day.

MiMedx Is Grand Sponsor Of Desert Foot 2016

MiMedx Is Grand Sponsor Of Desert Foot 2016

MiMedx EpiFix®, AmnioFix®, AmnioFill™ and EpiCord™ Showcased for Wound Healing and Surgical Procedures

MiMedx Third Quarter 2016 Revenue Exceeds Upper End Of Guidance

MiMedx Third Quarter 2016 Revenue Exceeds Upper End Of Guidance

$64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015

Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting

Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting

Presentation of Application Techniques and Therapeutic Approaches Using MiMedx EpiFix and AmnioFix for Wound Healing and Surgical Procedures

MiMedx Urges FDA To Reconsider Draft Guidances During Hearing

MiMedx Urges FDA To Reconsider Draft Guidances During Hearing

PRESENTERS OVERWHELMINGLY ASK FDA TO WITHDRAW OR SIGNIFICANTLY MODIFY DRAFT GUIDANCE

Scientific Study Confirms How MiMedx DHACM Allografts Effectively Promote Wound Repair

Scientific Study Confirms How MiMedx DHACM Allografts Effectively Promote Wound Repair

Study quantifies in MiMedx dHACM allografts numerous matrix components, growth factors, proteases and protease inhibitors known to play a role in wound healing

MiMedx Announces Nationwide Launch of AmnioFill™

MiMedx Announces Nationwide Launch of AmnioFill™

AMNIOFILL™ IS THE FIRST PRODUCT IN THE MIMEDX PLACENTAL COLLAGEN MATRIX FAMILY TO BE COMMERCIALLY INTRODUCED

MiMedx Provides Update On Key Clinical Trials

MiMedx Provides Update On Key Clinical Trials

FDA AGREES TO SHORTEN IMMUNOGENIC TESTING BY ONE YEAR IN THE COMPANY'S PLANTAR FASCIITIS STUDY

MiMedx Group (MDXG) Weak On High Volume

MiMedx Group (MDXG) Weak On High Volume

Trade-Ideas LLC identified MiMedx Group (MDXG) as a weak on high relative volume candidate

MiMedx Announces Nationwide Launch Of New Ambient Temperature Version Of OrthoFlo

MiMedx Announces Nationwide Launch Of New Ambient Temperature Version Of OrthoFlo

New Lyophilized OrthoFlo version is an advancement in product logistics and safety

MiMedx Second Quarter Of 2016 Revenue Exceeds Upper End Of Guidance Range

MiMedx Second Quarter Of 2016 Revenue Exceeds Upper End Of Guidance Range

$57.3 MILLION Q2 2016 REVENUE IS 26% INCREASE OVER Q2 2015

MiMedx Group Breaks Above 200-Day Moving Average - Bullish for MDXG

MiMedx Group Breaks Above 200-Day Moving Average - Bullish for MDXG

In trading on Friday, shares of MiMedx Group Inc crossed above their 200 day moving average of $8.34, changing hands as high as $8.38 per share. MiMedx Group Inc shares are currently trading up about 2.7% on the day.

MiMedx Adds New Executive

MiMedx Adds New Executive

Independent Clinical Case Series Demonstrates MiMedx DHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage

Independent Clinical Case Series Demonstrates MiMedx DHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage

Case series determines wounds with exposed bone or tendon treated with dHACM and STSG is viable low-cost treatment alternative to the gold standard for limb salvage

MiMedx Goes After Osiris With Lawsuit

MiMedx Goes After Osiris With Lawsuit

The wound care provider filed the suit for allegedly falsifying and misleading consumers with clinical data.

MiMedx Provides Reminder Of May 18th Annual Shareholders Meeting

MiMedx Provides Reminder Of May 18th Annual Shareholders Meeting

Company Reiterates Second Quarter Guidance

Trade-Ideas: MiMedx Group (MDXG) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: MiMedx Group (MDXG) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified MiMedx Group (MDXG) as a strong on high relative volume candidate